Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial

Table 3

Primary assessment method: overall assessment.

Parameter	N/(%)
Number of patients screened	41
Number of patients enrolled	39
Number of patients completed two cycles of neoadjuvant therapy	39
Number of patients evaluated toxicity	39
Number of patients evaluated tumor response	39
Number of patients received surgery	38
Radiological response	RECIST 1.1
CR	17 (43.6%)
PR	16 (41.0%)
SD	5 (12.3%)
PD	1 (2.5%)
ORR	84.6%
DCR	97.2%
R0 resection	37 (97.3%)
Pathological response
pCR	(93.6%)
MPR	15 (39.5%)
Downstaging rate	19 (48.7%)
Lymph nodes involved
ypN0	20 (51.35)
ypN1	11 (28.2%)
ypN2	6 (15.4%)
ypN3	2 (5.1%)